Gimv is the famous VC, which was founded in 1980. The main office of represented VC is situated in the Antwerpen. The fund was located in Europe if to be more exact in Belgium.
The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Neurotech, AgroSavfe, FIRE1 Among the most successful fund investment fields, there are Therapeutics, Enterprise Software. For fund there is a match between the location of its establishment and the land of its numerous investments - Belgium. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Gimv, startups are often financed by Sofinnova Partners, Novartis Venture Fund, 3i Group. The meaningful sponsors for the fund in investment in the same round are Neomed Management, Andera Partners, VI Partners AG. In the next rounds fund is usually obtained by Sofinnova Partners, Neomed Management, HBM Healthcare Investments AG.
Besides them, we counted 31 critical employees of this fund in our database.
The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. This Gimv works on 3 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2017. Considering the real fund results, this VC is 12 percentage points more often commits exit comparing to other organizations.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Onera Health | $35M | 16 Jan 2024 | Palo Alto, California, United States | ||
Complement Therapeutics | $84M | 17 Apr 2023 | London, England, United Kingdom | ||
Mediar Therapeutics | $85M | 15 Mar 2023 | Cambridge, Massachusetts, United States | ||
Paleo | $14M | 21 Feb 2023 | Leuven, Vlaams-Brabant, Belgium | ||
JenaValve Technology | $100M | 31 Aug 2022 | Munich, Bavaria, Germany | ||
ImCheck Therapeutics | $113M | 13 Jun 2022 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
ImmunOs Therapeutics | $77M | 07 Jun 2022 | Zurich, Switzerland | ||
Precirix | $94M | 16 Mar 2022 | City of Brussels, Belgium | ||
Anjarium Biosciences | $60M | 15 Sep 2021 | Schlieren, Zurich, Switzerland |
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Onera Health | $35M | 16 Jan 2024 | Palo Alto, California, United States | ||
Complement Therapeutics | $84M | 17 Apr 2023 | London, England, United Kingdom | ||
Mediar Therapeutics | $85M | 15 Mar 2023 | Cambridge, Massachusetts, United States | ||
Paleo | $14M | 21 Feb 2023 | Leuven, Vlaams-Brabant, Belgium | ||
JenaValve Technology | $100M | 31 Aug 2022 | Munich, Bavaria, Germany | ||
ImCheck Therapeutics | $113M | 13 Jun 2022 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
ImmunOs Therapeutics | $77M | 07 Jun 2022 | Zurich, Switzerland | ||
Precirix | $94M | 16 Mar 2022 | City of Brussels, Belgium | ||
Anjarium Biosciences | $60M | 15 Sep 2021 | Schlieren, Zurich, Switzerland |
